Testing nitazoxanide added to mesalamine for ulcerative colitis
Tests nitazoxanide with mesalamine in adults with ulcerative colitis, a chronic bowel inflammation.
Plain-language title generated from the registry record
Registry title: Nitazoxanide in Patients With Ulcerative Colitis
Key facts
- Where
- Alexandria, EgyptSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 with mild or moderate ulcerative colitis, confirmed by endoscopy and tissue testing.
- Age
- 18 to 65 years
- Sex
- Men and women can join.
- Disease stage
- Mild or moderate ulcerative colitis, already diagnosed and confirmed by endoscopy and histopathology (tissue examination).
- Earlier treatment
- People taking rectal or systemic steroids, immunosuppressives or biological therapies cannot join.
Main reasons for not taking part
- Breast feeding or pregnancy
- Colorectal cancer
- Severe ulcerative colitis
- Taking rectal or systemic steroids, immunosuppressives or biological therapies
- Addiction to alcohol and/or drugs
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06993974, who can take part
Where in Egypt
- Alexandria universityAlexandria, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alexandria University
- Trial code
- NCT06993974
- Record updated
- 27 June 2025
- Original description
Ulcerative colitis (UC) is a chronic inflammatory bowel Disease (IBD) that primarily affects the rectum and colon. The severity and persistence of mucosal inflammation are associated with morbidity and mortality.Read full original descriptionShow less
Clinical Study to Evaluate Safety and Efficacy of Nitazoxanide in Patients With Ulcerative Colitis.
Ulcerative colitis (UC) is a chronic inflammatory bowel Disease (IBD) that primarily affects the rectum and colon. The severity and persistence of mucosal inflammation are associated with morbidity and mortality.
Inclusion: Age ≥ 18 years; Both male and female will be included; Mild and moderate UC patients are already diagnosed and confirmed by endoscope and histopathology.
Exclusion: Patients taking rectal or systemic steroids; Patients taking immunosuppressives or biological therapies; Addiction to alcohol and / or drugs; Colorectal cancer patients; Known allergy to the studied medications; Breast feeding or pregnancy; Patients with severe UC.